Related Experiment Video

Updated: Apr 15, 2026

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.8K

Tumor heterogeneity: evolution through space and time in EGFR mutant non small cell lung cancer patients

Margarita Majem1, Jordi Remon2

  • 1Hospital de la Santa Creu i Sant Pau, Barcelona, Spain ;

Translational Lung Cancer Research
|March 26, 2015
PubMed

Insights

Non-small cell lung cancer (NSCLC) patients with EGFR mutations respond well to EGFR tyrosine kinase inhibitors (TKI). However, resistance develops, necessitating further research into mechanisms and new therapeutic strategies to improve patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations often show significant responses to EGFR tyrosine kinase inhibitors (TKI).
  • Despite initial efficacy, acquired resistance to EGFR TKI invariably develops, leading to disease progression.
  • A significant portion of acquired resistance mechanisms remain unexplained, highlighting a critical gap in understanding and treatment.

Purpose of the Study:

  • To review identified mechanisms of primary and acquired resistance to EGFR TKI in NSCLC.
  • To discuss potential therapeutic strategies to overcome EGFR TKI resistance.
  • To emphasize the importance of early and resistance-phase biopsies for uncovering novel resistance mechanisms and understanding response heterogeneity.

Main Methods:

  • Literature review of studies on EGFR TKI resistance in NSCLC.
  • Analysis of identified molecular mechanisms of resistance.
  • Discussion of emerging therapeutic strategies.

Main Results:

  • Several mechanisms contributing to primary and acquired resistance to EGFR TKI have been identified.
  • These mechanisms offer potential targets for novel therapeutic interventions.
  • Up to 30% of acquired resistance cases still lack a clear molecular explanation.

Conclusions:

  • Understanding EGFR TKI resistance mechanisms is crucial for developing effective treatment strategies in NSCLC.
  • Further research, including comprehensive biopsy analysis, is needed to elucidate unexplained resistance and personalize therapy.
  • Targeting identified resistance pathways and exploring novel therapeutic approaches hold promise for improving outcomes in EGFR-mutated NSCLC.
Keywords:
Primary resistanceacquired resistanceepidermal growth factor receptornon-small cell lung cancer

More Related Videos

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

25.2K
Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation10:24

Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation

Published on: September 19, 2019

6.9K

Related Concept Videos

Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
8.0K
Tumor Progression02:07

Tumor Progression

3.6K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.6K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
15.7K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

3.6K
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
56.3K